New Potential Therapy for Ovarian Cancer: Stearoyl-CoA Desaturase-1 (SCD1) Inhibition with the Novel Compound SSI-4
ISEF · 2018 Translational Medical Science
Overview
Purpose: The experiment identified Stearoyl-CoA desaturase 1 (SCD1) as a novel molecular target in Serous Ovarian Carcinoma determined the potential of SSI-4, an SCD1 inhibitor, as a novel molecular inhibitor. SCD1 catalyzes a double bond in the cis-delta-9 position of saturated fatty acids transforming them into monounsaturated fatty acids promoting membrane synthesis and cell proliferation. Following determination of specificity and efficacy of SSI-4, cell death mechanism was examined through protein analysis. Experimental Design: Four Serous Ovarian cell lines were examined for SCD1 expression through Western Blot. Specificity of SSI-4 was determined through the rescue of the phenotype (Oleic acid) after SSI-4 treatment. Efficacy was determined through proliferation assays. Finally, the apoptotic mechanism of cell death was examined through Western Blots. Results: These studies identify SCD1 expression in all four lines tested. The phenotypic rescue of SSI-4 treated drugs concludes that SSI-4 is specific to SCD1 and anti-proliferative results are not due to off target effects. The proliferation assay of various SSI-4 concentrations concluded SSI-4 treatment results in a dose-dependent decrease in cell proliferation. Protein analysis detected Endoplasmic reticulum stress binding immunoglobulin protein, as well as apoptosis proteins Survivin and Cleaved Caspase 3. Conclusion: SCD1 expression coupled with promising dose-dependency and specificity of SSI-4 in vitro indicates the drug's therapeutic potential as a small molecule inhibitor in Serous Ovarian Carcinoma. Protein analysis implicates apoptosis as the primary mechanism of cell death. As a small molecule inhibitor, SSI-4 could be used independently and alongside platinum and or taxol therapies currently in use.
Competition history
- ISEF 2018
Resources
Related projects
ISEF · 2020
Hierarchically Engineered Nanotheranostic for Ovarian Cancer
ISEF · 2014
Seeking a Cure II: Targeting ERß in a Novel Cost-Effective Treatment for Ovarian Epithelial Cancer
ISEF · 2019
p53-Bad: A Novel Mitochondrially Targeted Gene Therapy for Ovarian Cancer
ISEF · 2022
Testing the Effects of Anti-DLL4 Monoclonal Antibody in Conjunction With Tamoxifen Hormone Therapy Treated Ovarian Cancer
ISEF · 2025
Decoding PDAC: A scRNA-seq Omics Analysis to Unveil and Inhibit Key Protein Using a Novel in-silico, Structure-Based Drug Design Pipeline
ISEF · 2017
Necrosis of Lung Adenocarcinoma by Targeting a Novel Egg-Specific Protein
ISEF · 2022
Altering Metabolic Pathways To Override Drug Resistance in Cancer
ISEF · 2023
The Effects of APC Loss on Response to Chemotherapy in Ovarian Cancer Cells
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair